Imaging apolipoprotein AI in vivo

Renuka Sriram, Jens O. Lagerstedt, Jitka Petrlova, Haris Samardzic, Ulrike Kreutzer, Hongtao Xie, George Kaysen, Jean F. Desreux, David Thonon, Vincent Jacques, Martha Van Loan, John C Rutledge, Michael N. Oda, John C Voss, Thomas Jue

Research output: Contribution to journalArticlepeer-review

12 Scopus citations


Coronary disease risk increases inversely with high-density lipoprotein (HDL) level. The measurement of the biodistribution and clearance of HDL in vivo, however, has posed a technical challenge. This study presents an approach to the development of a lipoprotein MRI agent by linking gadolinium methanethiosulfonate (Gd[MTS-ADO3A]) to a selective cysteine mutation in position 55 of apo AI, the major protein of HDL. The contrast agent targets both liver and kidney, the sites of HDL catabolism, whereas the standard MRI contrast agent, gadolinium-diethylenetriaminepentaacetic acid-bismethylamide (GdDTPA-BMA, gadodiamide), enhances only the kidney image. Using a modified apolipoprotein AI to create an HDL contrast agent provides a new approach to investigate HDL biodistribution, metabolism and regulation in vivo.

Original languageEnglish (US)
Pages (from-to)916-924
Number of pages9
JournalNMR in Biomedicine
Issue number7
StatePublished - Aug 2011


  • Apolipoprotein
  • Cardiovascular risk
  • Contrast agent
  • Gadolinium
  • HDL
  • MRI
  • NMR

ASJC Scopus subject areas

  • Spectroscopy
  • Molecular Medicine
  • Radiology Nuclear Medicine and imaging


Dive into the research topics of 'Imaging apolipoprotein AI in vivo'. Together they form a unique fingerprint.

Cite this